The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.

Elijah O. Kehinde, May A. Maghrebi, Jehoram T. Anim

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Incidental prostate cancer (PCa) has been demonstrated at autopsy in about 80% of men aged 80 years and above and also in 10%-15% of younger men aged 30-50 years in the United States. These data imply a wide variation in aggressiveness of prostate cancer, from indolent tumors to aggressive cancers that kill the patients. The use of prostate specific antigen (PSA) in screening for PCa may detect even indolent disease for which radical prostatectomy may not be necessary. Currently available criteria such as histological grade, PSA level, stage of the disease do not always predict outcome. Furthermore, only about 80% of men with metastatic PCa will respond to first line hormone manipulation and once the patient develops hormone resistant prostate cancer (HRPCa), survival remains poor. Recent genomic and proteomic studies have provided many novel molecular markers that may help to redefine prognostic parameters. This paper is a review of studies using these novel markers in order to determine whether prostate cancer patients with the following characteristics have more aggressive cancer than those without: a) high serum levels of cathepsin B, survivin, Her - 2 / neu, IGFBP-2; b) low serum stefin A, IGFBP-3, c) positive immuno-staining of primary tumors for Her-2/neu, survivin and cathepsin B / stefin A ratio > 1 and d) gene expression of AMACR, HER-2/neu, high Bcl-2: Bax ratio and EZH2 in cancer cells. These markers have been chosen for review because they are among the most promising markers emerging currently.

Original languageEnglish
Pages (from-to)3967-3974
Number of pages8
JournalCanadian Journal of Urology
Volume15
Issue number2
Publication statusPublished - Apr 2008
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Cystatin A
Serum
Cathepsin B
Neoplasms
Prostate-Specific Antigen
Hormones
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Protein 3
Prostatectomy
Proteomics
Autopsy
Prostate Cancer, Hereditary, 7
Staining and Labeling
Gene Expression
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. / Kehinde, Elijah O.; Maghrebi, May A.; Anim, Jehoram T.

In: Canadian Journal of Urology, Vol. 15, No. 2, 04.2008, p. 3967-3974.

Research output: Contribution to journalReview article

Kehinde, Elijah O. ; Maghrebi, May A. ; Anim, Jehoram T. / The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. In: Canadian Journal of Urology. 2008 ; Vol. 15, No. 2. pp. 3967-3974.
@article{3d0ed73ac2194d018c7d53e89641e463,
title = "The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.",
abstract = "Incidental prostate cancer (PCa) has been demonstrated at autopsy in about 80{\%} of men aged 80 years and above and also in 10{\%}-15{\%} of younger men aged 30-50 years in the United States. These data imply a wide variation in aggressiveness of prostate cancer, from indolent tumors to aggressive cancers that kill the patients. The use of prostate specific antigen (PSA) in screening for PCa may detect even indolent disease for which radical prostatectomy may not be necessary. Currently available criteria such as histological grade, PSA level, stage of the disease do not always predict outcome. Furthermore, only about 80{\%} of men with metastatic PCa will respond to first line hormone manipulation and once the patient develops hormone resistant prostate cancer (HRPCa), survival remains poor. Recent genomic and proteomic studies have provided many novel molecular markers that may help to redefine prognostic parameters. This paper is a review of studies using these novel markers in order to determine whether prostate cancer patients with the following characteristics have more aggressive cancer than those without: a) high serum levels of cathepsin B, survivin, Her - 2 / neu, IGFBP-2; b) low serum stefin A, IGFBP-3, c) positive immuno-staining of primary tumors for Her-2/neu, survivin and cathepsin B / stefin A ratio > 1 and d) gene expression of AMACR, HER-2/neu, high Bcl-2: Bax ratio and EZH2 in cancer cells. These markers have been chosen for review because they are among the most promising markers emerging currently.",
author = "Kehinde, {Elijah O.} and Maghrebi, {May A.} and Anim, {Jehoram T.}",
year = "2008",
month = "4",
language = "English",
volume = "15",
pages = "3967--3974",
journal = "Canadian Journal of Urology",
issn = "1195-9479",
publisher = "Canadian Journal of Urology",
number = "2",

}

TY - JOUR

T1 - The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers.

AU - Kehinde, Elijah O.

AU - Maghrebi, May A.

AU - Anim, Jehoram T.

PY - 2008/4

Y1 - 2008/4

N2 - Incidental prostate cancer (PCa) has been demonstrated at autopsy in about 80% of men aged 80 years and above and also in 10%-15% of younger men aged 30-50 years in the United States. These data imply a wide variation in aggressiveness of prostate cancer, from indolent tumors to aggressive cancers that kill the patients. The use of prostate specific antigen (PSA) in screening for PCa may detect even indolent disease for which radical prostatectomy may not be necessary. Currently available criteria such as histological grade, PSA level, stage of the disease do not always predict outcome. Furthermore, only about 80% of men with metastatic PCa will respond to first line hormone manipulation and once the patient develops hormone resistant prostate cancer (HRPCa), survival remains poor. Recent genomic and proteomic studies have provided many novel molecular markers that may help to redefine prognostic parameters. This paper is a review of studies using these novel markers in order to determine whether prostate cancer patients with the following characteristics have more aggressive cancer than those without: a) high serum levels of cathepsin B, survivin, Her - 2 / neu, IGFBP-2; b) low serum stefin A, IGFBP-3, c) positive immuno-staining of primary tumors for Her-2/neu, survivin and cathepsin B / stefin A ratio > 1 and d) gene expression of AMACR, HER-2/neu, high Bcl-2: Bax ratio and EZH2 in cancer cells. These markers have been chosen for review because they are among the most promising markers emerging currently.

AB - Incidental prostate cancer (PCa) has been demonstrated at autopsy in about 80% of men aged 80 years and above and also in 10%-15% of younger men aged 30-50 years in the United States. These data imply a wide variation in aggressiveness of prostate cancer, from indolent tumors to aggressive cancers that kill the patients. The use of prostate specific antigen (PSA) in screening for PCa may detect even indolent disease for which radical prostatectomy may not be necessary. Currently available criteria such as histological grade, PSA level, stage of the disease do not always predict outcome. Furthermore, only about 80% of men with metastatic PCa will respond to first line hormone manipulation and once the patient develops hormone resistant prostate cancer (HRPCa), survival remains poor. Recent genomic and proteomic studies have provided many novel molecular markers that may help to redefine prognostic parameters. This paper is a review of studies using these novel markers in order to determine whether prostate cancer patients with the following characteristics have more aggressive cancer than those without: a) high serum levels of cathepsin B, survivin, Her - 2 / neu, IGFBP-2; b) low serum stefin A, IGFBP-3, c) positive immuno-staining of primary tumors for Her-2/neu, survivin and cathepsin B / stefin A ratio > 1 and d) gene expression of AMACR, HER-2/neu, high Bcl-2: Bax ratio and EZH2 in cancer cells. These markers have been chosen for review because they are among the most promising markers emerging currently.

UR - http://www.scopus.com/inward/record.url?scp=50349094623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50349094623&partnerID=8YFLogxK

M3 - Review article

VL - 15

SP - 3967

EP - 3974

JO - Canadian Journal of Urology

JF - Canadian Journal of Urology

SN - 1195-9479

IS - 2

ER -